At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 75 enrolled
Drug / intervention
Glucagon Nasal Powder +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients With Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Glucagon Nasal Powder and Glucagon Hydrochloride Solution for Diabetes Mellitus. Completed, enrolled 75 participants across 4 sites.
Detailed Summary
The purpose of this study is to determine the efficacy and safety of nasal glucagon compared to intramuscular (IM) glucagon for treatment of insulin-induced hypoglycemia in Japanese participants with diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartFeb 2018
Primary CompletionAug 2018
TodayJul 2026
First PostedFeb 5, 2018
Enrollment StartFeb 21, 2018
Primary CompletionAug 20, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.4 years ago
Interventions
Glucagon Nasal Powderdrug
Administered intranasally
Glucagon Hydrochloride Solutiondrug
Administered IM